Everything below concerns lyophilisation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-09. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
The convoy scattered, and Gaddafi and those closest to him fled to a nearby villa, which was shelled by rebel militia from Misrata. Fleeing to a construction site, Gaddafi and his inner cohort hid inside drainage pipes while his bodyguards battled the rebels; in the conflict, Gaddafi suffered head injuries from a grenade blast while Jabr was killed. The Misrata militia took Gaddafi prisoner, causing serious injuries as they tried to apprehend him; the events were filmed on a mobile phone. A video appears to picture Gaddafi being poked or stabbed in the anus "with some kind of stick or knife" or possibly a bayonet. Pulled onto the front of a pick-up truck, he fell off as it drove away. His semi-naked body was then placed into an ambulance and taken to Misrata; upon arrival, he was found to be dead. Official NTC accounts claimed that Gaddafi was caught in a crossfire and died from bullet wounds. Other eye-witness accounts claimed that rebels had fatally shot Gaddafi in the stomach. That afternoon, NTC Prime Minister Mahmoud Jibril publicly revealed the news of Gaddafi's death. His corpse was placed in the freezer of a local market alongside the corpses of Yunis Jabr and Mutassim; the bodies were publicly displayed for four days, with Libyans from all over the country coming to view them. Footage of Gaddafi's death was broadcast extensively across media networks internationally. In response to international calls, on 24 October Jibril announced that a commission would investigate Gaddafi's death.
=== Ga–Go === Elmer L. Gaden (1923–2012). American biochemical engineer at the University of Virginia, known as the father of biochemical engineering. Michael H. Gelb (b. 1957). American biochemist at the University of Washington who studies study enzymatic processes of biomedical significance. Susan Gerbi, (b. 1944). American biochemist at Brown University working on RNA and DNA. Jonathan Gershenzon (b. 1955). American biochemist at the Max Planck Institute for Chemical Ecology in Jena, known for work on the biochemistry of secondary plant metabolites. Quentin Gibson FRS (1918–2011). British-American biochemist at Sheffield and later Cornell University who worked on haem proteins. Member Natl. Acad. Sci. USA. Walter Gilbert FRS (foreign member) (b. 1932). American biochemist at Harvard, awarded the Nobel Prize in Chemistry (1980) for work on DNA sequencing. Member Natl. Acad. Sci. USA. H. Bentley Glass (1906–2005). American biochemist at the State University of New York at Stony Brook. Member Natl. Acad. Sci. USA Joseph L. Goldstein (b. 1940). American biochemist at the University of Texas, awarded the Nobel Prize in Physiology or Medicine (1985) for studies of cholesterol. Member Natl. Acad. Sci. USA. Eugene Goldwasser (1922–2010). American biochemist at the University of Chicago, known for identifying the hormone erythropoietin. Michael M. Gottesman (b. 1946). American biochemist at the NIH, whose achievements includes the discovery of P-glycoprotein. Member Natl. Acad. Sci. USA. Alfred Gottschalk (1894–1973).
An acre-foot is a unit of volume commonly used in the United States in reference to large-scale water resources, such as reservoirs, aqueducts, canals, sewer flow capacity, irrigation water and river flows. It is defined by the volume of one acre of surface area to a depth of one foot. 43,560 ft3 (1,233 m3; 325,851 US gal; 271,328 imp gal).
J. League Manager of the Year: 1995 Onze d'Or Coach of The Year: 2000, 2002, 2003, 2004 Premier League Manager of the Season: 1997–98, 2001–02, 2003–04 LMA Manager of the Year: 2001–02, 2003–04 BBC Sports Personality of the Year Coach Award: 2002, 2004 London Football Awards – Outstanding Contribution to a London Club: 2015 World Soccer Manager of the Year: 1998 FWA Tribute Award: 2005 English Football Hall of Fame: 2006 France Football Manager of the Year: 2008 IFFHS World Coach of the Decade: 2001–2010 Facebook FA Premier League Manager of the Year: 2014–15 Premier League Manager of the Month: March 1998, April 1998, October 2000, April 2002, September 2002, August 2003, February 2004, August 2004, September 2007, December 2007, February 2011, February 2012, September 2013, March 2015, October 2015 France Football 32nd Greatest Manager of All Time: 2019 World Soccer 36th Greatest Manager of All Time: 2013 Laureus Lifetime Achievement Award: 2019 Premier League Hall of Fame: 2023 Orders
Sources: en.wikipedia.org
=== Modern occurrence === During the post Civil war period in Spain, there were several outbreaks of lathyrism, caused by the shortage of food, which led people to consume excessive amounts of almorta flour. In Spain, a seed mixture known as comuña consisting of Lathyrus sativus, L. cicera, Vicia sativa and V. ervilia provides a potent mixture of toxic amino acids to poison monogastric (single stomached) animals. Particularly the toxin β-cyanoalanine from seeds of V. sativa enhances the toxicity of such a mixture through its inhibition of sulfur amino acid metabolism (conversion of methionine to cysteine leading to excretion of cystathionine in urine) and hence depletion of protective reduced thiols. Its use for sheep does not pose any lathyrism problems if doses do not exceed 50 percent of the ration.
In 2024, circana tracked approximately 11,000 unauthorized flavored disposable vape products in U.S. mainstream retail outlets, according to data reviewed by Reuters. In 2024, illegal sales of flavored disposable vapes reached about $2.4 billion and accounted for roughly 35% of all e-cigarette sales in mainstream retail outlets. According to data reviewed by Reuters, Circana estimated the total tracked vape market at $6.8 billion, excluding online and specialty store sales. A 2025 lawsuit by New York's attorney general cited testimony that one distributor sold more than $132 million worth of Elf Bar e-cigarettes in the prior year. Altria Group, one of the largest tobacco companies in the United States and the owner of Philip Morris USA, has significant investments in the domestic e-cigarette market. In January 2025, Altria said it was reassessing its 2028 "smoke-free" volume and revenue goals, citing competition from disposable vapes, and estimated that illicit disposable products represent 60% or more of the U.S. e-cigarette category despite lacking required authorizations. US authorities reported intensified enforcement actions against unauthorized e-cigarettes in 2025, including seizures of 4.7 million units valued at $86.5 million in a Chicago-based operation; US agencies also reported blocking more than 6 million unauthorized e-cigarettes worth over $120 million that year.
On 8 April, authorities in Islamabad declared public holidays for 9 and 10 April in the federal capital to facilitate the upcoming talks. Government offices and educational institutions were ordered to remain closed, while essential services such as police, hospitals, and utilities continued to operate. Extensive security measures were implemented across the capital, with reports indicating the deployment of more than 10,000 police and security personnel, supported by paramilitary forces and military coordination. The city was placed on high alert, with strict restrictions on movement and heightened surveillance in key areas. The Serena Hotel in Islamabad, located within the heavily secured Red Zone near key government buildings and foreign embassies, was requisitioned to host the delegations. Guests were asked to vacate the premises ahead of the talks, and the facility was designated as the primary venue for negotiations. The Red Zone was sealed, and multiple entry points into Islamabad were closed as part of a wider security cordon. Authorities also implemented traffic diversion plans across major roads, including the Express Highway, advising residents to adjust travel plans due to expected disruptions. According to officials, the security arrangements included coordination between Islamabad Police, Punjab Police, Rangers, and other security agencies to ensure protection for visiting delegations and control movement across the capital.
=== Board member controversy === Tevanian left Apple on March 31, 2006, and joined the boards of both Dolby Labs and Theranos, Inc. He resigned from the board of Theranos in late 2007, with an acrimonious ending as he faced legal threats and was forced to waive his right to buy a company co-founder's shares, actions he believed were in retaliation for the scepticism he was often alone in expressing about the company's finances and progress in developing its technology at board meetings. In 2019, Tevanian gave a wide-ranging interview on his time at Theranos for a six-part podcast series called The Dropout, produced by ABC News. In the interview, he said: "I had seen so many things that were bad go on. I would never expect anyone would behave the way that she [Elizabeth Holmes] behaved as a CEO. And believe me, I worked for Steve Jobs. I saw some crazy things. But Elizabeth took it to a new level.”
To adopt a functional three-dimensional shape, the polypeptide chain must first form a series of smaller underlying structures called secondary structures. The polypeptide chain in these secondary structures then folds to produce the overall 3D tertiary structure. Once correctly folded, the protein can undergo further maturation through different post-translational modifications, which can alter the protein's ability to function, its location within the cell (e.g. cytoplasm or nucleus) and its ability to interact with other proteins. Protein biosynthesis has a key role in disease as changes and errors in this process, through underlying DNA mutations or protein misfolding, are often the underlying causes of a disease. DNA mutations change the subsequent mRNA sequence, which then alters the mRNA encoded amino acid sequence. Mutations can cause the polypeptide chain to be shorter by generating a stop sequence which causes early termination of translation. Alternatively, a mutation in the mRNA sequence changes the specific amino acid encoded at that position in the polypeptide chain. This amino acid change can impact the protein's ability to function or to fold correctly. Misfolded proteins have a tendency to form dense protein clumps, which are often implicated in diseases, particularly neurological disorders including Alzheimer's and Parkinson's disease.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。